Search

The article reports that a white paper outlining the status of drug supervision in China has been released by the country's State Food and Drug Administration (SFDA). It is noted that China has a nationwide information network for monitoring adverse drug reactions (ADRs) since 2002, making electronic and real-time reporting feasible. Other activities undertaken by the SFDA include the establishment of a drug classification system.